Surviving a year of the haves and have-nots

Investors expect 2023 to be a tale of two sectors: continued interest in companies with de-risked or late-stage assets, and a struggle for survival for those without.

According to 14 buysiders and bankers who spoke to BioCentury, there are several reasons to be positive headed into the new year. First, the market is showing signs of improved health: companies’ share prices are being rewarded for positive news with the ability to raise capital and see that performance hold in the aftermarket; and M&A is continuing to draw interest in late-stage and commercial assets...